Monday, June 10, 2019. Specialized magazine Journal of Experimental Medicine He reported that Mexico's Maximiliano Medina Ramírez, a postdoctoral researcher at the University of Amsterdam's Academic Medical Center in the Netherlands, has developed an experimental vaccine to prevent human immunodeficiency virus (HIV) infection.
So far, the prototype vaccine has only been applied to mice, and although it has yielded good results, it still has to wait a few months to enter a next stage of testing to be applied to humans and then produce it on a large scale.
For scientific development, Mexicans employed protein engineering techniques that allowed them to stabilize the trimer, which is what "envelops" the HIV virus and is used to infect through traps or deceptions to the immune system.
In addition to trimer stabilization, the structure has been modified to favor the activation of bNAbs precursor B cells, which have the ability to prevent the spread of the virus and which are developed in almost half of people living with HIV a year of maintenance of an infection active
However, at this time and when these antibodies were produced naturally, the virus has already found where to hide from the immune system.
ANDSo the task of Dr. Medina Ramirez was to select these antibodies and to adapt them through the engineering of proteins to design a vaccine that stimulates the immune system to develop bNAbs before the virus attacks.
"We are currently in the stage of scale production of this experimental vaccine. The goal is to start a clinical study over the next twelve months, "said the biotechnology engineer graduated from the University of Sonora.
The Mexican scientist recognizes that, thanks to Conacyt's support, he has managed to be a postdoctoral researcher at the Academic Medical Center of the University of Amsterdam in the Netherlands and was also able to publicize his work.
The investigation also had a fund of the foundation Aids Fonds of the Netherlands, focused on funding HIV research, while the Bill and Melinda Gates Foundation is providing funds to conduct the clinical trial in which the second version of the prototype will be tested.
The results were published in the journal Journal of Experimental Medicine in the title "Design and crystal structure of a native HIV-1 envelope trimer involving multiple broadly neutralizing antibody precursors in vivo."